Akèy › Limfom Difize Gwo Selil B › Nebraska › Omaha
Etid klinik pou Limfom Difize Gwo Selil B nan Omaha, NE
9 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan ak bò kote Omaha (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Ap rekriteFaz 2
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 mi lwen
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Ap rekriteFaz 2/3
- Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0177), Omaha
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Ap rekriteFaz 2
- University Of Nebraska Medical Center ( Site 0110), Omaha
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Ap rekriteFaz 1
- The University of Nebraska Medical Center, Omaha
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Ap rekriteFaz 2
- Nebraska Cancer Specialists, Omaha
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- University of Nebraska Medical Center, Omaha
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- University of Nebraska Medical Center (UNMC), Omaha
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Ap rekriteFaz 1/2
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Ap rekriteFaz 2
- Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha
Etid Limfom Difize Gwo Selil B nan lòt vil
- New York City, NY21 etid
- Baldwin Park, CA19 etid
- Chicago, IL18 etid
- Los Angeles, CA17 etid
- Houston, TX17 etid
- Boston, MA16 etid
- Milwaukee, WI16 etid
- Portland, OR15 etid
- Philadelphia, PA15 etid
- Durham, NC14 etid
- Nashville, TN14 etid
- Dallas, TX13 etid
Lòt etid nan Omaha
- Kansè pwostat28 etid
- Kansè Poumon ki pa ti selil25 etid
- Kansè nan tete23 etid
- Kansè (tout kalite)19 etid
- Kansè kolorektal19 etid
- Myelom Miltip16 etid
- Kansè ovè15 etid
- Kansè pankreyas14 etid
- Kansè Metastatik14 etid
- Limfòm Non-Hodgkin14 etid
- Ensifizyans kadyak13 etid
- Kansè poumon13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.